Table 1 Baseline characteristics of the patients.

From: Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment

 

Total

 

(n = 122)

Clinical factor

Age (years)

45 (23–79)

Sex (male)

78 (63.9%)

Body mass index (kg/m2)

22.3 (14.7–38.9)

Cirrhosis

22 (18.0%)

HCC family history ( +)

11 (9.0%)

Previous interferon treatment ( +)

25 (20.5%)

Alcohol consumption ( +)

17 (13.9%)

Cigarette smoking ( +)

41 (33.6%)

Diabetes mellitus ( +)

7 (5.7%)

Fatty liver ( +)

36 (29.5%)

Platelet count (×103/mm3)

165 (50–403)

Aspartate aminotransferase (U/L)

72 (22–872)

Alanine aminotransferase (U/L)

113 (16–2605)

γ-glutamyltransferase (U/L)

52 (10–474)

Total bilirubin (mg/dL)

0.8 (0.2–31.1)

Albumin (g/dL)

4.1 (2.1–5.0)

Prothrombin time (%)

88 (33–134)

α-fetoprotein (ng/mL)

5.8 (< 2.0–903.8)

HBV genotype (A/B/C/D/N.D.)

3/12/104/1/2

HBeAg positivity

59 (48.4%)

HBsAg (log IU/mL)

3.53 (-0.85–5.35)

HBV-DNA (log copies/mL)

7.3 (3.1– > 9.1)

Precore G1896A

39 (32.0%)

Basic core promoter A1762T/G1764A

85 (69.7%)

Hyaluronic acid (ng/mL)

71.7 (< 10–1480)

Type III procollagen-N-peptide (U/mL)

0.9 (0.4–3.9)

Type IV collagen (ng/mL)

179 (88–695)

M2BPGi (C.O.I)

1.25 (0.24–12.29)

AST to platelet ratio index

1.45 (0.26–26.16)

Fibrosis-4 index

2.11 (0.54–12.16)

Treatment duration (years)

6.2 (1.1–13.3)

Soluble immune checkpoint proteins

sBTLA (pg/mL)

92.36 (4.88–7379.58)

sCD27 (pg/mL)

2240.59 (275.77–90,205.76)

sCD28 (pg/mL)

1829.45 (452.34–40,812.96)

sTIM-3 (pg/mL)

3182.68 (22.39–26,629.55)

sHVEM (pg/mL)

2806.94 (514.79–34,673.87)

sCD40 (pg/mL)

482.43 (217.88–14,447.65)

sGITR (pg/mL)

0.49 (0.49–1195.54)

sLAG-3 (pg/mL)

10,062.07 (870.17–101,198.27)

sTLR-2 (pg/mL)

337.92 (131.75–8434.07)

sGITRL (pg/mL)

26.67 (2.441–1233.55)

sPD-1 (pg/mL)

523.72 (131.95–6310.53)

sCTLA-4 (pg/mL)

14.46 (2.84–301.54)

sCD80 (pg/mL)

12.18 (1.22–4117.63)

sCD86 (pg/mL)

334.07 (56.92–6589.98)

sPD-L1 (pg/mL)

23.23 (1.64–550.01)

sICOS (pg/mL)

89.96 (4.88–3717.92)

  1. The values are medians (with ranges) or numbers (with percentages).
  2. HBV, hepatitis B virus; N.D., not determined; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; sBTLA, soluble B- and T-lymphocyte attenuator; sCD27, soluble CD27; sCD28, soluble CD28; sTIM-3, soluble T-cell immunoglobulin and mucin domain-3; sHVEM, soluble herpes virus entry mediator; sCD40, soluble CD40; sGITR, soluble glucocorticoid-induced TNFR-related; sLAG-3, soluble lymphocyte-activation gene 3; sTLR-2, soluble toll-like receptor 2; sGITRL, soluble glucocorticoid-induced TNFR-related ligand; sPD-1, soluble programmed cell death-1; sCTLA-4, soluble cytotoxic T-lymphocyte associated antigen 4; sCD80, soluble CD80; sCD86, soluble CD86; sPD-L1, soluble programmed cell death-ligand 1; sICOS, soluble inducible T-cell co-stimulator.
Back to article page